Navigation Links
Morbidity higher in obese liver transplant recipients with diabetes
Date:1/23/2014

Researchers from New Zealand report that morbidity following liver transplant is highest among obese patients with diabetes, but these risk factors do not influence post-transplant survival. According to the study published in Liver Transplantation, a journal of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, body mass index (BMI) is effective for assessing obesity in liver transplant patients.

One of the greatest health concerns in developed countries is the increase in obesity, diabetes, and metabolic syndrome, which is a combination of high blood pressure (hypertension), blood sugar (hyperglycaemia), and cholesterol (dyslipidemia) along with increased belly fat. In fact, the World Health Organization (WHO) reported in 2008 that 1.4 billion adults were overweight, and of these 200 million men and 300 million women were obese.

Prior research shows that liver transplant recipients who develop post-transplant diabetes and metabolic syndrome are at increased risk of cardiovascular disease. Moreover, while death and graft loss resulting from organ rejection has improved in past 30 years, up to 42% of non-graft related deaths are attributed to cardiovascular disease according to a 2002 study by Vogt et al.

"There is much evidence on post-transplant obesity and metabolic syndrome. However, the impact of pre-transplant obesity, hypertension and coronary artery disease on post-transplant outcomes has received less attention and is the focus of our study." said lead author Dr. Adam Bartlett with the New Zealand Liver Transplant Unit at Auckland City Hospital.

For the present study, researchers recruited 202 consecutive patients undergoing liver transplantation at a New Zealand center between 2000 and 2010. BMI and percentage of body fat were measured before the transplant to compare methods. Analyses of pre-transplant risk factors such as obesity, diabetes, coronary artery disease were conducted.

Participants undergoing liver transplant had a mean age of 51 years and 67% were male with most common reason for being hepatitis C cirrhosis. The BMI was available for 192 patients4% were underweight, 27% normal weight, 26% overweight, 28% obese, 9% severely obese and 6% morbidly obese. Researchers determined that BMI and measured body fat were similar in 86% of the study group.

Further analyses indicate that obesity was an independent risk factor for diabetes and post-transplant complications. Diabetes in conjunction with obesity was the strongest predictor of complications following transplant and longer hospital stays. Metabolic risk factors did not affect 30-day, 1-year or 5-year survival for liver transplant recipients.

"Our study confirms that BMI is an appropriate measure of body fat and obesity alone should not prevent patients from receiving liver transplants," concludes Dr. Bartlett. "Identifying modifiable risk factors during the pre-transplant assessment allows for earlier interventions including weight control, diabetes management, and coronary interventions such as stenting, all which may improve long-term outcomes following liver transplantation."


'/>"/>
Contact: Dawn Peters
sciencenewsroom@wiley.com
781-388-8408
Wiley
Source:Eurekalert

Related medicine news :

1. Lowering the national ozone standard would significantly reduce mortality and morbidity
2. Higher-spending hospitals have fewer deaths for emergency patients
3. Taller, Heavier Women May Face Higher Ovarian Cancer Risk
4. Heart failure patients with diabetes may benefit from higher glucose levels
5. Cancer Care Costs Higher in U.S. Than Europe, But Survival Longer
6. Children Born to Obese Moms May Face Higher Autism Risk: Study
7. Could Menthol Cigarettes Pose Even Higher Stroke Risk?
8. Certain Birth Control Pills May Carry Higher Blood Clot Risk: FDA
9. Mental Illness Tied to Higher Rates of Physical Problems: Report
10. Overweight Pregnant Women at Higher Risk for Complications
11. Depression Linked to Higher Odds for Poor Leg Circulation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... ... “The Journey: From the Mountains to the Mission Field”: the story of ... Philippines. “The Journey: From the Mountains to the Mission Field” is the creation of ... taught all ages and currently teaches a class of ladies at her church, which ...
(Date:10/12/2017)... CA (PRWEB) , ... October 12, 2017 , ... ... Cheng, are now treating sleep apnea using cutting-edge Oventus O2Vent technology. ... a serious sleep disorder characterized by frequent cessation in breathing. Oral appliances can ...
(Date:10/12/2017)... ... 12, 2017 , ... IsoComforter, Inc. ( https://isocomforter.com ), one of ... innovative new design of the shoulder pad. The shoulder pad provides optimal support ... your pain while using cold therapy. By utilizing ice and water that is circulated ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the ... to develop to enable prevention of a major side effect of chemotherapy in ... in pediatric patients. For cisplatin, hearing loss is FDA listed on-label as a ...
(Date:10/12/2017)... ... October 12, 2017 , ... Leading pediatric oncology experts at ... for the 49th Congress of the International Society of Paediatric Oncology (SIOP) ... Center for Cancer and Blood Disorders at Children’s National, and Stephen P. ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... , Oct. 2, 2017 Halo Labs announces the ... analysis system called the HORIZON at MIBio 2017 in ... subvisible and visible particulate matter in biopharmaceutical samples with unprecedented speed ... of the novel technique Backgrounded Membrane Imaging. ... The HORIZON subvisible particle analysis system ...
(Date:9/27/2017)... for their devotion to personalized service, SMP Pharmacy Solutions announces ... the South Florida Business Journal,s 50 Fastest-Growing Companies, and listed ... national specialty pharmacy has found its niche.  To that end, ... honored by SFBJ as the 2017 Power Leader in Health ... his award in October, Bardisa said of the three achievements, ...
(Date:9/23/2017)... , Sept. 22, 2017 Janssen Biotech, Inc. ... response letter from the U.S. Food and Drug Administration ... of sirukumab for the treatment of moderately to severely ... additional clinical data are needed to further evaluate the ... severely active RA. ...
Breaking Medicine Technology: